说明:欢迎约稿、业务洽谈、媒体合作及行业交流。如需加入行业交流群,或发现内容涉及侵权需修改,请联系小助手微信:Taaslabs18信达和礼来的合作再次点燃了创新药板块,全行业投资者们再次看到了创新药企业出海的魅力。出海,仍然是创新药板块未来几年之内的主旋律,只是各家药企所采用的方式有所不同,有的biotech用license out的方式,有的大型biopharma用co-co的模式,还有的...
Source Link说明:欢迎约稿、业务洽谈、媒体合作及行业交流。如需加入行业交流群,或发现内容涉及侵权需修改,请联系小助手微信:Taaslabs18信达和礼来的合作再次点燃了创新药板块,全行业投资者们再次看到了创新药企业出海的魅力。出海,仍然是创新药板块未来几年之内的主旋律,只是各家药企所采用的方式有所不同,有的biotech用license out的方式,有的大型biopharma用co-co的模式,还有的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.